497843-21-7

Basic information

• Product Name: 4-Pyridinecarboxylic acid, 1,2,3,6-tetrahydro-1-(phenylmethyl)-5-[[(trifluoromethyl)sulfonyl]oxy]-, ethyl ester
• CAS NO: 497843-21-7
• Molecular Formula: C16H18F3NO5S
• Molecular Weight: 393.384
• Mol File: 497843-21-7.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 4-Pyridinecarboxylic acid, 1,2,3,6-tetrahydro-1-(phenylmethyl)-5-[[(trifluoromethyl)sulfonyl]oxy]-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyridinecarboxylic acid, 1,2,3,6-tetrahydro-1-(phenylmethyl)-5-[[(trifluoromethyl)sulfonyl]oxy]-, ethyl ester(497843-21-7)
• EPA Substance Registry System: 4-Pyridinecarboxylic acid, 1,2,3,6-tetrahydro-1-(phenylmethyl)-5-[[(trifluoromethyl)sulfonyl]oxy]-, ethyl ester(497843-21-7)

Safety Data

• Hazardous Substances Data: 497843-21-7(Hazardous Substances Data)

Upstream product

• 37595-74-7 N,N-phenylbistrifluoromethane-sulfonimide 
• 358-23-6 trifluoromethylsulfonic anhydride 
• 52763-21-0 ethyl 1-benzyl-3-oxopiperidine-4-carboxylate hydrochloride 
• 39514-19-7 ethyl 1-benzyl-3-oxo-4-piperidinecarboxylate 

Downstream Products

• 873846-90-3 Ethyl 1-benzyl-5-(2-(methoxycarbonyl)-4-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine-4-carboxylate 
• 1076229-73-6 ethyl 1-benzyl-5-[2-(1-methylethyl)phenyl]-1,2,3,6-tetrahydropyridine-4-carboxylate 
• 1357587-00-8 ethyl 1-benzyl-5-(2-methylphenyl)-1,2,3,6-tetrahydropyridine-4-carboxylate 
• 1076229-69-0 1-tert-butyl 4-ethyl 3-(2-methylphenyl)piperidine-1,4-dicarboxylate 
• 1076229-74-7 1-tert-butyl 4-ethyl 3-(2-isopropylphenyl)piperidine-1,4-dicarboxylate 
• 1357586-44-7 1-benzyl-5-phenyl-1,2,3,6-tetrahydropyridine-4-carboxylic acid hydrochloride 

Relevant articles and documents

HETEROCYCLIC COMPOUND

The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).

NK1 RECEPTOR ANTAGONIST

A problem of the present invention is to provide a new compound which has NK1 receptor antagonist activity, and thus is useful for the prevention or treatment of cancer-chemotherapy-induced nausea and vomiting. A compound represented by the formula (I): wherein W represents a fluorine atom and the like, ring A represents a cycloalkyl and the like, X1 represents CH or N, R represents methyl and the like, Y represents 0 to 2, U1, U2 and U3 each independently represents a single bond and the like, or a pharmaceutically acceptable salt thereof. The compounds of the present invention or pharmaceutically acceptable salts thereof have an excellent NK1 receptor antagonist activity, and thus are also useful as an agent for the prevention or treatment of cancer-chemotherapy-induced nausea and vomiting.

PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS

The present invention relates to a compounds of formula I wherein A, Ar1, Ar2, R1, R2, R3, R4, R5, R6, m, n, o, p, s, t, and u are as defined herein or to a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof. the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).